Why Cancer Doctors Stood and Applauded
The video highlights a landmark phase‑III trial of Directinib, a novel KRAS inhibitor, that elicited a standing‑ovation from oncologists because it finally cracks a target long labeled “undruggable.” In the study of 500 metastatic pancreatic‑cancer patients across six countries, oral Directinib extended median overall survival to 13.2 months versus 6.6 months for standard chemotherapy, effectively adding six months of life in a disease where five‑year survival is under 13%. Unlike earlier KRAS drugs that only fit the rare G12C mutation, Directinib hijacks the abundant protein cyclophilin A to lock KRAS in its active state, shutting down signaling across multiple KRAS variants—including the dominant G12D in pancreatic tumors. The applause reflected both the survival gain and the proof‑of‑concept that KRAS can be drugged. The breakthrough opens a pathway for treating roughly one‑fifth of all cancers driven by KRAS, and early combination studies pairing Directinib with agents targeting complementary vulnerabilities (e.g., MTAP loss) have shown tumor shrinkage in 11 of 12 patients. If replicated, this strategy could reshape therapeutic algorithms for pancreatic, lung, colorectal and other KRAS‑mutant malignancies.
Can Wearables Become Clinical Tools? | Longevity News Roundup — Week 24, 2026
The episode explores how emerging AI platforms and wearables are moving into clinical longevity practice, covering Longevitics’ new intelligence system, a continuous cortisol sensor, and a landmark animal‑health partnership. Longevitics aggregates labs, wearable streams, notes and intake forms, then runs them...
How AI Is Transforming Clinical Trial Patient Recruitment
The video explains how artificial intelligence is reshaping clinical‑trial patient recruitment by moving from broad, untargeted marketing to precise, data‑driven matching. Instead of inviting anyone through the door and then sifting through medical histories, AI algorithms analyze eligibility criteria up...
AI Agents Start Shopping, AI Designs Vaccines and Zero Trust Gets Serious | Techstrong Gang
The panel discussed the emerging wave of AI‑driven shopping assistants, highlighted by OpenAI’s new partnership with Visa to embed autonomous agents directly into credit‑card transactions. These agents can monitor user preferences, track price fluctuations, and execute purchases automatically when predefined...
AGDD 2025 | D2S04 - Nitrosamines: Known Issues and Practical Advice
The final session of the Advancing Generic Drug Development Workshop tackled nitrosamine impurities in immediate‑release oral generics, focusing on the unique challenges posed by BCS 4 drug substances. Presenters highlighted that out of roughly 160 nitrosamine‑impacted products, a substantial share falls...
How Speed and Scale Can Drive Innovation in Cancer Care
Dr. Edward Kim, Physician‑in‑Chief of City of Hope’s Orange County campus, outlined a bold strategy to reshape cancer care through what he calls the "speed, scale, serve" model. By opening a new facility in Orange County, the network not only...
Pharmacovigilance in Practice From Safety Signals to Regulatory Action 1080
FDA Grand Rounds presenters from the Center for Drug Evaluation and Research’s Division of Pharmacovigilance (DPV) outlined how the agency conducts postmarket drug safety surveillance, defining pharmacovigilance and the criteria for safety signals. They described DPV’s team structure aligned to...
Conversations on Cancer: Patient First = Project Facilitate
The Oncology Center of Excellence’s Project Facilitate, launched at ASCO in 2019, provides a centralized, patient‑first service that helps physicians navigate single‑patient INDs and expanded‑access pathways for investigational oncology therapies. Panelists explained how the program evolved from a simple...
Gene Editing Risks: VERVE 102 Diabetes Concerns Explored #shorts
The video outlines Verve 102, a CRISPR‑based base‑editing therapy that permanently disables the PCSK9 gene to dramatically lower LDL cholesterol. Verve 102 uses a Cas9‑derived base editor that chemically flips one nucleotide, shutting off PCSK9 production. The therapeutic mRNA and guide...
Dr. Glaucomflecken Explains: Transdermal Estradiol in Prostate Cancer
The video discusses a New England Journal of Medicine trial that compared transdermal estradiol patches with luteinizing hormone‑releasing hormone (LHRH) agonists in men with locally advanced prostate cancer. The study enrolled men who could not tolerate conventional androgen‑deprivation therapy and...
What if We Stopped Waiting for People to Win the Genetic Lottery and Simply Gave Them the Ticket?
The video discusses Verve 102, a one‑time gene‑editing therapy designed to mimic the natural loss‑of‑function mutations in the PCSK9 gene that keep LDL cholesterol low and protect against heart attacks. Researchers have identified that roughly 2.6 % of Black participants carry nonsense PCSK9...
Nutrition Scientist Dr. Federica Amati: Why It's So Hard to Lose Weight and Keep It Off
Dr. Federica Amati, head of nutrition science at Zoe, explains why losing weight and keeping it off remains a biological challenge and how emerging GLP‑1 medications are reshaping the landscape. She frames the conversation around her new book, *The Appetite...
NEJM Clinician: Are PPIs Linked to COPD Flares?
The NEJM Clinician video examines whether proton‑pump inhibitors (PPIs) contribute to increased COPD flare‑ups. It highlights a recent claims‑based analysis of more than 900,000 patients with obstructive airway disease, comparing those prescribed PPIs to those who were not, while controlling...
The Women's Health Initiative 20 Years Later
The video revisits the 2002 Women’s Health Initiative (WHI) trials, emphasizing that the studies enrolled women averaging 63 years—well beyond the typical perimenopausal window—and tested hormone therapy (HT) as a preventive measure, not as symptom relief. The combined estrogen‑progestin arm...
Did One Tiny Tweak Just Solve Heart Disease?
The video examines Verve Therapeutics’ breakthrough gene‑editing therapy, Verve 102, which uses a CRISPR‑derived base editor to permanently silence the PCSK9 gene in liver cells, aiming to eradicate the primary driver of atherosclerotic heart disease—elevated LDL cholesterol. In the latest NEJM‑published trial,...